Holen Sie sich die Stockscreener-App
22.50
0.24%
-0.055
Schlusskurs vom Vortag:
$22.56
Offen:
$22.63
24-Stunden-Volumen:
320.40K
Relative Volume:
0.06
Marktkapitalisierung:
$11.24B
Einnahmen:
$4.89B
Nettoeinkommen (Verlust:
$-242.00M
KGV:
-46.02
EPS:
-0.489
Netto-Cashflow:
$315.00M
1W Leistung:
+0.11%
1M Leistung:
-2.87%
6M Leistung:
-5.68%
1J Leistung:
+12.30%
1-Tages-Spanne:
$22.37
$22.77
1-Wochen-Bereich:
$22.00
$22.98
52-Wochen-Spanne:
$19.40
$27.98
Elanco Animal Health Inc Stock (ELAN) Company Profile
Firmenname
Elanco Animal Health Inc
Sektor
Telefon
877-352-6261
Adresse
450 ELANCO CIRCLE, INDIANAPOLIS
Compare ELAN vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
22.50 | 11.24B | 4.89B | -242.00M | 315.00M | -0.489 |
TAK
Takeda Pharmaceutical Co Adr
|
18.63 | 59.51B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.46 | 48.35B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.46 | 41.60B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
74.95 | 30.97B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
544.89 | 23.37B | 3.17B | 1.29B | 1.01B | 27.09 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Citigroup | Buy |
| 2026-01-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-11-21 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2025-11-19 | Hochstufung | Argus | Hold → Buy |
| 2025-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-07-17 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-06-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-12-09 | Eingeleitet | UBS | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-09-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-01-05 | Hochstufung | Stifel | Hold → Buy |
| 2023-12-19 | Eingeleitet | Jefferies | Buy |
| 2023-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-07 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2023-04-20 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-21 | Herabstufung | Goldman | Buy → Sell |
| 2022-07-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-11-18 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-28 | Herabstufung | Stifel | Buy → Hold |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-06-15 | Hochstufung | Cleveland Research | Underperform → Neutral |
| 2021-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2021-05-11 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2021-04-15 | Eingeleitet | Stifel | Buy |
| 2021-03-22 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2021-02-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-09 | Herabstufung | Argus | Buy → Hold |
| 2020-11-09 | Herabstufung | Barclays | Overweight → Underweight |
| 2020-08-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-08-13 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-08-04 | Fortgesetzt | Goldman | Buy |
| 2020-07-27 | Herabstufung | Cleveland Research | Neutral → Underperform |
| 2020-04-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-10 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-19 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-11-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-23 | Eingeleitet | Barclays | Overweight |
| 2019-08-26 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-08-15 | Hochstufung | UBS | Sell → Neutral |
| 2019-05-23 | Eingeleitet | Guggenheim | Neutral |
| 2019-03-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-03-13 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-02-12 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-23 | Eingeleitet | UBS | Sell |
| 2019-01-15 | Eingeleitet | Argus | Buy |
| 2018-10-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Elanco Animal Health Inc Aktie (ELAN) Neueste Nachrichten
Deferring cash fees, Elanco (ELAN) director Kapila K. Anand acquires 642 stock-linked units. - stocktitan.net
Elanco Animal Health CEO Jeffrey N. Simmons Reports Acquisition of Deferred Stock Units - Kalkine Media
Form 4 Elanco Animal Health For: 22 September By Investing.com - Investing.com Nigeria
Form 4 Elanco Animal Health For: 22 September By Investing.com - Investing.com Canada
Elanco Animal Health (ELAN) CEO adds 126 deferred stock units - Stock Titan
Elanco (NYSE: ELAN) exec adds 65.8756 deferred stock units - Stock Titan
Elanco (NYSE: ELAN) CFO now holds 158.6535 deferred stock units - Stock Titan
Elanco Animal Health Incorporated (ELAN) Latest Press Releases & Corporate News - finance.yahoo.com
Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement - Yahoo Finance
Elanco to Participate in Morgan Stanley 24th Annual Global Healthcare Conference - PR Newswire
Elanco Animal Health (ELAN) CFO receives 8 deferred stock units - Stock Titan
Deferred stock award lifts Elanco Animal Health (NYSE: ELAN) exec's holdings - Stock Titan
Elanco (NYSE: ELAN) CEO adds to deferred pay with new stock grant - Stock Titan
Elanco Animal Health (ELAN) 10K Form and Latest SEC Filings 2026 - MarketBeat
Mutts With a Mission: How Elanco and Medical Mutts Transform Lives Together - CSRwire
Elanco Animal Health Stock Price Forecast. Should You Buy ELAN? - StockInvest.us
Elanco Director Purchases 40,000 Shares for $936,000 - Yahoo Finance
Elanco Director Purchases 40,000 Shares for $936,000 - The Motley Fool
Elanco Animal Health Inc (ELAN) Stock Price, Quote, News & History - Benzinga
Is Elanco Animal Health Inc (ELAN) Overvalued After 3.2% Rally? - GuruFocus
Pharma clinical research firm eyes former Elanco building in Greenfield - Indianapolis Business Journal
Elanco Animal Health (ELAN) Institutional Ownership 2026 $ELAN - MarketBeat
Elanco Scales Biologics Capabilities With Expansion of Kansas Manufacturing Facility - marketscreener.com
Elanco Scales Biologics Capabilities With Expansion of Kansas Manufacturing Facility - finance.yahoo.com
Elanco Animal Health (ELAN) Stock Analysis: Unveiling a 29% Upside Potential Amidst Robust Revenue Growth - DirectorsTalk Interviews
Elanco Says Demand for Its New Dog Treatment Is Twice What Was Expected - Stock Titan
Elanco (NYSE: ELAN) EVP now holds 9,770 deferred units - Stock Titan
Elanco Animal Health CEO Jeffrey N. Simmons Acquires 117.94 Deferred Stock Units - kalkinemedia.com
Elanco (NYSE: ELAN) reports new insider share trade - Stock Titan
Elanco (NYSE: ELAN) CFO holds 141.8242 deferred stock units - Stock Titan
Elanco Animal Health CFO Robert M. VanHimbergen Acquires 8.22 Deferred Stock Units - Kalkine Media
US Insider Trades Show Shifts In Key Names - TradingPedia
Top insider buys and sells disclosed on Friday - Investing.com
Top insider buys and sells disclosed on Friday By Investing.com - Investing.com South Africa
Elanco Animal Health (ELAN) Stock Analysis: Unlocking a 30% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
Elanco Animal Health (NYSE:ELAN) Director Lawrence Erik Kurzius Purchases 40,000 Shares - MarketBeat
Elanco director Kurzius buys $935,920 in company stock - Investing.com
Elanco director Kurzius buys $935,920 in company stock - Investing.com
Elanco Animal Health Director Purchased Shares Worth Over $935K - TradingView
Elanco (NYSE: ELAN) director buys 40K shares, stake now 188,647 - Stock Titan
Danske Bank A S Makes New $14.35 Million Investment in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health Inc (ELAN) Shares Fall 3.8% -- What GF Scor - GuruFocus
Stifel reiterates Buy rating on Elanco stock, $33 target By Investing.com - Investing.com Canada
245,707 Shares in Elanco Animal Health Incorporated $ELAN Purchased by Great Lakes Advisors LLC - MarketBeat
Elanco Animal Health: New Products To Support Growth (NYSE:ELAN) - Seeking Alpha
Attention investors: You may be eligible for a $15 million Elanco Animal Health SEC fair fund payment - Claim Depot
Elanco Animal Health (NYSE:ELAN): Is More Momentum Ahead? - Kalkine Media
CNBC Final Trades: Netflix, Eli Lilly, Elanco Animal Health & MoreNetflix (NASDAQ:NFLX), Eli Lilly (NY - Benzinga
160,631 Shares in Elanco Animal Health Incorporated $ELAN Purchased by First National Bank of Omaha - MarketBeat
Director's Confidence Visible as Elanco Leader Buys 10,000 Shares - Yahoo Finance
Finanzdaten der Elanco Animal Health Inc-Aktie (ELAN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Elanco Animal Health Inc-Aktie (ELAN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| O'Neill Shiv | GC AND CORP SEC |
Aug 18 '26 |
Buy |
23.58 |
3,998 |
94,273 |
87,832 |
| Harrington Michael J | Director |
Aug 12 '26 |
Buy |
21.82 |
5,000 |
109,100 |
131,451 |
| VanHimbergen Robert M | EVP and CFO |
Aug 07 '26 |
Buy |
23.08 |
4,200 |
96,926 |
137,516 |
| Herendeen Paul | Director |
Aug 07 '26 |
Buy |
23.68 |
10,000 |
236,850 |
111,687 |
| Modi Rajeev A. | SEE REMARKS |
May 15 '26 |
Buy |
20.35 |
4,911 |
99,939 |
160,812 |
| Simmons Jeffrey N | PRESIDENT, CEO AND DIRECTOR |
May 15 '26 |
Buy |
20.09 |
4,971 |
99,843 |
171,971 |
| Kurzius Lawrence Erik | Director |
Dec 12 '25 |
Buy |
21.30 |
10,000 |
213,000 |
131,773 |
| Modi Rajeev A. | SEE REMARKS |
Dec 11 '25 |
Buy |
21.33 |
4,500 |
95,985 |
123,082 |
| VanHimbergen Robert M | EVP and CFO |
Dec 11 '25 |
Buy |
21.64 |
6,950 |
150,426 |
124,233 |
| Simmons Jeffrey N | PRESIDENT, CEO AND DIRECTOR |
Dec 11 '25 |
Buy |
21.75 |
22,000 |
478,496 |
167,000 |
0.04%
3.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):